OLMA

Olema Pharmaceuticals, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1750284Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(162.0M)

EPS (Basic, as reported)

$-1.87

Net Margin FY2025

—

ROE FY2025

-33.9%

Total Equity

$479.0M

Shares Out

87M

Business description

Olema Pharmaceuticals, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (4) → (162)

Fiscal yearFY2019⚑FY2020⚑FY2021FY2022FY2023FY2024⚑FY2025

Research & development(4)(14)(51)(82)(86)(125)(158)

General & administrative0(8)(20)(25)(19)(18)(21)

Total operating expenses(4)(22)(71)(107)(105)(142)(179)

Operating income(4)(22)(71)(107)(105)(142)(179)

Interest expense—(1)—————

Interest & investment income000281316

Other income (expense), net0(1)0281316

Pre-tax income—————(129)(162)

Income tax expense———0000

Net income(4)(22)(71)(105)(97)(129)(162)

EPS — basic($1.66)($3.42)($1.80)($2.62)($2.14)($2.20)($1.87)

EPS — diluted($1.66)($3.42)($1.80)($2.62)($2.14)($2.20)($1.87)

Shares outstanding — basic (M)374040455987

Shares outstanding — diluted (M)374040455987

⚑ Weighted-average shares changed ×2.33 between FY2019 and FY2020 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×5.71 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.47 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.